生命科学资讯

Amgen buys protein-degrading startup Dark Blue for up to $840M

CDC, following Trump’s orders, weakens US stance on childhood vaccinations

Surfing the AI wave: How pharma can harness agents in ERP

Moderna, searching for a rebound, to seek approval of mRNA flu shot

Zenas shares crash after top drug misses expectations in immune disease study

Novo launches Wegovy pill; Argenx to swap CEOs

10 clinical trials to watch in the first half of 2026

Strategic diagnostic testing partnerships are accelerating clinical research

Novo Nordisk’s weight loss pill approved by FDA

Biopharma CEO optimism is wavering in the US

Biopharma climbs higher as 9 drugmakers ink ‘pandering’ drug price deals with Trump

Trump to test ‘most favored nation’ pricing for Medicare; Shionogi pays $2.5B for ALS drug

Radiopharmaceutical specialist Aktis seeks an IPO

Cytokinetics set to battle Bristol Myers as FDA approves heart drug

Patient deaths put Merck, Daiichi’s ADC trial on partial hold

BioMarin to buy rare disease drugmaker Amicus for $4.8B

Novo files for CagriSema approval; Merck and Pfizer’s trial win

Galapagos TYK2 drug hits goal in one trial, misses in another

Moderna gets funding for H5 pandemic influenza vaccine

Lilly obesity pill, headed for quick FDA review, hits mark in ‘maintenance’ trial